OMEROS CORP Interest and Other Income
OMEROS CORP (OMER) reported Interest and Other Income of $4.63 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Other Income
us-gaap:InterestAndOtherIncome · last filed 2026-08-12
- OMEROS CORP interest and other income for the quarter ending 2026-06-30 was $4.63M, a 272.76% increase year-over-year.
- OMEROS CORP interest and other income for the quarter ending 2026-03-31 was $1.48M, a 31.34% increase year-over-year.
- OMEROS CORP interest and other income for the quarter ending 2025-12-31 was $1.12M, a 50.94% decline year-over-year.
- OMEROS CORP interest and other income for the quarter ending 2025-09-30 was $616.00K, a 73.74% decline year-over-year.
- OMEROS CORP interest and other income for fiscal 2025 was $4.10M, a 63.70% decline from fiscal 2024.
- OMEROS CORP interest and other income for fiscal 2024 was $11.29M, a 30.94% decline from fiscal 2023.
- OMEROS CORP interest and other income for fiscal 2023 was $16.34M, a 302.31% increase from fiscal 2022.
- OMEROS CORP interest and other income for fiscal 2022 was $4.06M, a 133.45% increase from fiscal 2021.
| Period end | Interest and Other Income 3 month | Interest and Other Income 3 month as first filed | Interest and Other Income 6 month | Interest and Other Income 9 month | Interest and Other Income 12 month | Interest and Other Income 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $4.63M 10-Q · filed 2026-08-12 | $6.10M 10-Q · filed 2026-08-12 | $7.22M derived: sum of 3 quarters · filed 2026-08-12 | $7.83M derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2026-03-31 | $1.48M 10-Q · filed 2026-05-13 | $2.59M derived: sum of 2 quarters · filed 2026-05-13 | $3.21M derived: sum of 3 quarters · filed 2026-05-13 | $4.45M derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2025-12-31 | $1.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $1.73M derived: sum of 2 quarters · filed 2026-03-31 | $2.97M derived: sum of 3 quarters · filed 2026-08-12 | $4.10M 10-K · filed 2026-03-31 | ||
| 2025-09-30 | $616.00K 10-Q · filed 2025-11-13 | $1.86M derived: sum of 2 quarters · filed 2026-08-12 | $2.98M 10-Q · filed 2025-11-13 | $5.26M derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2025-06-30 | $1.24M 10-Q · filed 2026-08-12 | $2.36M 10-Q · filed 2026-08-12 | $4.64M derived: sum of 3 quarters · filed 2026-08-12 | $6.99M derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2025-03-31 | $1.12M 10-Q · filed 2026-05-13 | $1.06M 10-Q · filed 2025-05-15 | $3.40M derived: sum of 2 quarters · filed 2026-05-13 | $5.75M derived: sum of 3 quarters · filed 2026-05-13 | $8.99M derived: sum of 4 quarters · filed 2026-05-13 | |
| 2024-12-31 | $2.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $4.62M derived: sum of 2 quarters · filed 2026-03-31 | $7.87M derived: sum of 3 quarters · filed 2026-03-31 | $11.29M 10-K · filed 2026-03-31 | $11.30M 10-K · filed 2025-03-31 | |
| 2024-09-30 | $2.35M 10-Q · filed 2025-11-13 | $5.59M derived: sum of 2 quarters · filed 2025-11-13 | $9.01M 10-Q · filed 2025-11-13 | $12.44M derived: sum of 4 quarters · filed 2026-03-31 | ||
| 2024-06-30 | $3.25M 10-Q · filed 2025-08-14 | $6.66M 10-Q · filed 2025-08-14 | $10.09M derived: sum of 3 quarters · filed 2026-03-31 | $14.50M derived: sum of 4 quarters · filed 2026-03-31 | ||
| 2024-03-31 | $3.42M 10-Q · filed 2025-05-15 | $6.84M derived: sum of 2 quarters · filed 2026-03-31 | $11.26M derived: sum of 3 quarters · filed 2026-03-31 | $15.79M derived: sum of 4 quarters · filed 2026-03-31 | ||
| 2023-12-31 | $3.43M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $7.84M derived: sum of 2 quarters · filed 2026-03-31 | $12.38M derived: sum of 3 quarters · filed 2026-03-31 | $16.34M 10-K · filed 2026-03-31 | ||
| 2023-09-30 | $4.41M 10-Q · filed 2024-11-13 | $8.95M derived: sum of 2 quarters · filed 2024-11-13 | $12.91M 10-Q · filed 2024-11-13 | $14.91M derived: sum of 4 quarters · filed 2025-03-31 | ||
| 2023-06-30 | $4.54M 10-Q · filed 2024-08-07 | $8.50M 10-Q · filed 2024-08-07 | $10.49M derived: sum of 3 quarters · filed 2025-03-31 | $11.40M derived: sum of 4 quarters · filed 2025-03-31 | ||
| 2023-03-31 | $3.96M 10-Q · filed 2024-05-15 | $5.96M derived: sum of 2 quarters · filed 2025-03-31 | $6.86M derived: sum of 3 quarters · filed 2025-03-31 | $7.53M derived: sum of 4 quarters · filed 2025-03-31 | ||
| 2022-12-31 | $1.99M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $2.90M derived: sum of 2 quarters · filed 2025-03-31 | $3.57M derived: sum of 3 quarters · filed 2025-03-31 | $4.06M 10-K · filed 2025-03-31 | ||
| 2022-09-30 | $906.00K 10-Q · filed 2023-11-09 | $1.58M derived: sum of 2 quarters · filed 2023-11-09 | $2.07M 10-Q · filed 2023-11-09 | $2.60M derived: sum of 4 quarters · filed 2024-04-01 | ||
| 2022-06-30 | $670.00K 10-Q · filed 2023-08-09 | $1.16M 10-Q · filed 2023-08-09 | $1.69M derived: sum of 3 quarters · filed 2024-04-01 | $2.15M derived: sum of 4 quarters · filed 2024-04-01 | ||
| 2022-03-31 | $493.00K 10-Q · filed 2023-05-09 | $1.02M derived: sum of 2 quarters · filed 2024-04-01 | $1.48M derived: sum of 3 quarters · filed 2024-04-01 | |||
| 2021-12-31 | $528.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $989.00K derived: sum of 2 quarters · filed 2024-04-01 | $1.74M 10-K · filed 2024-04-01 | |||
| 2021-09-30 | $461.00K 10-Q · filed 2022-11-09 | $1.21M 10-Q · filed 2022-11-09 | ||||
| 2020-12-31 | $654.00K 10-K · filed 2023-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |